Project Grant R35HL177241
Award Date
4/15/25
Completion Date
1/31/32
Dollars Obligated
$1.1M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Iowa City, IA 52242, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $587,249 to support research into the role of the CDK8 mediator kinase in regulating cardiac gene expression and its potential as a therapeutic target for pathological cardiac hypertrophy and heart failure. The key objectives are to: 1) evaluate small-molecule CDK8 inhibitors for therapeutic potential, 2) identify novel CDK8...
This federal Project Grant award, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), will support research to investigate the physiological function of the junctophilin-1 (JP1) protein in cardiac muscle and its potential significance in heart disease. The $684,937 award, spanning from March 2025 to December 2028, will enable researchers at the University of Iowa to utilize their existing mouse models to better...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), awarded a $846,536 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Beckman Research Institute of the City of Hope. The funding will support research to characterize the role of the RPS6KB1 protein as an integrative player in pathological cardiac remodeling and the development of hypertensive heart disease and heart failure. Key objectives include further...
The federal Project Grant award of $540,856 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support research to identify transcriptional regulators of endocardial-restricted gene expression, determine how valve-restricted expression is achieved, and define the regulation and function of the SLC16A2 gene during heart injury and regeneration. The research aims to improve understanding of the cellular and molecular...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $817,208 Project Grant under the Cardiovascular Diseases Research Program (CFDA 93.837) to The Broad Institute, Inc. (doing business as Broad Institute of MIT and Harvard) to conduct research aimed at identifying novel genes and biological mechanisms underlying heart failure. The project will leverage high-throughput genomic and functional screening approaches, including cell painting and Perturb-seq assays, to systematically...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) totaling $1,451,467 provides funding to the University of California, San Diego (UC San Diego) from July 1, 2024 to June 30, 2028. The award supports a multi-disciplinary research project investigating the developmental regulators and gene regulatory networks that direct the formation of diverse cardiovascular cell types from juxta-cardiac field progenitors in the...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $249,000 Project Grant to the University of Arkansas to develop microphysiological systems that can precisely control oxygen levels and monitor the effects on cardiomyocyte function. The goal is to gain a comprehensive understanding of the molecular pathways activated and the resulting impacts on cardiomyocyte behavior in response to hypoxic cardiac injury, such as...
The federal Project Grant award under the Cardiovascular Diseases Research program (CFDA 93.837) from the National Heart, Lung, and Blood Institute (NHLBI) will provide $243,000.00 from January 1, 2025 to December 31, 2026 to the University of Cincinnati. This exploratory study aims to address challenges related to the efficiency and specificity of converting fibroblasts (connective tissue cells) into cardiac cells for in vivo heart regeneration. The research will focus on innovatively...
This $847,164 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to understand the underlying mechanisms of pathologic remodeling of Purkinje cells in the ventricular conduction system. The research aims to provide a deep mechanistic understanding of how paracrine signaling from activated fibroblasts may drive Purkinje cell transcriptional remodeling, leading to repression of rapid...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $784,046 to the University of Virginia to fund research aimed at improving treatment of acute myocardial infarction (AMI) and preventing heart failure. The project will utilize computational modeling and cell-specific experiments to investigate how the signaling receptor LRP1 influences cardiomyocyte survival and fibroblast activity...